Compare Bit Digital Inc (BTBT) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bit Digital Inc vs Crispr Therapeutics AG — how do they compare? Bit Digital Inc trades at $1.66 (market cap $581.34M), while Crispr Therapeutics AG trades at $50.54 (market cap $4.97B). The key difference: Crispr Therapeutics AG is far larger — about 8.5× Bit Digital Inc's market cap. Which is the better fit depends on your goals.
| BTBT | CRSP | |
|---|---|---|
Market Cap | $581.34M | $4.97B |
Sector | Technology | Health |
52-Week High | $4.22 | $76.78 |
52-Week Low | $1.27 | $44.34 |
Enterprise Value | $870.65M | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTBT trades at $1.64, down 2.96% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $80.32 million in 2025 with a -145.45% net income margin, missing earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.
Despite 100% analyst buy ratings, BTBT faces significant fundamental challenges with persistent losses and negative cash flow from operations. The stock's appeal hinges on turnaround execution and crypto market recovery, but high volatility and operational risks warrant caution for investors.
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
